LABORATORY RESEARCH In Vitro and In Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer Most compounds are more cytotoxic to a number of human cancer cell lines than cisplatin. Scientists indicated that the cell death type for these compounds is mainly through canonical or caspase-dependent apoptosis, non-dependent on p53, and that the compounds do not interact with DNA or inhibit protease cathepsin B. [J Med Chem] Abstract 2-(4-Hydroxy-3-Methoxyphenyl)-Benzothiazole Suppresses Tumor Progression and Metastatic Potential of Breast Cancer Cells by Inducing Ubiquitin Ligase CHIP Scientists show that a novel agent, 2-(4-hydroxy-3-methoxyphenyl)-benzothiazole, has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. [Sci Rep] Full Article Elevated 14,15- Epoxyeicosatrienoic Acid by Increasing of Cytochrome P450 2C8, 2C9 and 2J2 and Decreasing of Soluble Epoxide Hydrolase Associated with Aggressiveness of Human Breast Cancer The level of 14,15-epoxyeicosatrienoic acid (EET)/14,15-DHET in breast cancer patients was detected by ELISA; the expression and distribution of CYP2C8, 2C9, 2J2 and soluble epoxide hydrolase was determined by quantitative RT-PCR and immunohistochemical staining; and cell proliferation and migration was analyzed by MTT and transwell assays, respectively. [BMC Cancer] Abstract | Full Article miR-429 Inhibits Migration and Invasion of Breast Cancer Cells In Vitro Scientists established an in vivo bone metastasis model of breast cancer by injecting MDA-MB-231 cells into the left ventricle of nude mice, and then screened the differentially expressed microRNAs (miRNAs) between parental and bone-metastatic MDA-MB-231 cells using miRNA array. [Int J Oncol] Abstract Cotylenin A and Arsenic Trioxide Cooperatively Suppress Cell Proliferation and Cell Invasion Activity in Human Breast Cancer Cells Scientists found that cotylenin A, a plant growth regulator and a potent inducer of differentiation in myeloid leukemia cells, significantly potentiated both arsenic trioxide (ATO)-induced inhibition of cell growth in a liquid culture, and ATO-induced inhibition of anchorage-independent growth in a semi-solid culture in human breast cancer MCF-7 and MDA-MB-231 cells. [Int J Oncol] Abstract The Role of NOS-Mediated ROS Accumulation in an Early Phase Cu-Induced Acute Cytotoxicity in MCF-7 Cells Researchers provide data showing that high level of CuCl2 could rapidly decrease the nitric oxide production with the release of Ca2+ and Zn2+, and then modulate the transcriptional and translational expression of nitric oxide synthases in MCF-7 cells. [Biometals] Abstract Ionizing Radiation Sensitizes Breast Cancer Cells to Bcl-2 Inhibitor, ABT-737, through Regulating Mcl-1 Researchers demonstrate that the combination of ABT-737 and radiation-induced apoptosis had an inhibitory effect on breast cancer cell proliferation. However, treatment with ABT-737 resulted in elevated myeloid cell leukemia 1 (Mcl-1) in breast cancer cell lines. [Radiat Res] Abstract CLINICAL RESEARCH Anti-Proliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Pre-Surgical Randomized MAPLE Trial (CRUK E/06/039) Women with primary breast cancers were randomized to 10-14 days of pre-operative lapatinib or placebo in a multicenter Phase II trial. Biopsies pre-/post-treatment were analyzed for Ki67, apoptosis, HER2, EGFR, ER, PgR, pAKT, pERK, & stathmin by IHC. [Cancer Res] Abstract Zoledronic Acid Combined with Adjuvant Endocrine Therapy of Tamoxifen versus Anastrozol plus Ovarian Function Suppression in Premenopausal Early Breast Cancer: Final Analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Zoledronic acid plus adjuvant endocrine therapy significantly improved disease-free survival at 48 and 62 months’ follow-up in the ABCSG-12 trial. The authors present efficacy results of a final additional analysis after 94.4 months. [Ann Oncol] Abstract Subcutaneous versus Intravenous Formulation of Trastuzumab for HER2-Positive Early Breast Cancer: Updated Results from the Phase III HannaH Study Patients were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with three-weekly subcutaneous trastuzumab or the standard weight-based IV method. Following surgery, patients continued trastuzumab treatment to complete one year of therapy. [Ann Oncol] Abstract Dose-Dense Paclitaxel versus Docetaxel following FEC as Adjuvant Chemotherapy in Axillary Node-Positive Early Breast Cancer: A Multicenter Randomized Study of the Hellenic Oncology Research Group (HORG) Scientists conducted a randomized study to compare the efficacy of dose-dense paclitaxel versus docetaxel following 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) as adjuvant chemotherapy in women with node-positive early breast cancer. [Breast Cancer Res Treat] Abstract |